10/16/20 4:10 PMNasdaq : KRYSKrystal Biotech Announces Departure of Chief Commercial OfficerKrystal Biotech, Inc. (Nasdaq:KRYS) today announced that Chief Commercial Officer Jennifer Chien is leaving the company, effective today, to pursue another opportunity. Senior members of Krystal's commercial team will report directly to Chief Executive Officer Krish Krishnan on an interim basis as the company initiates a search for Ms. Chien's replacement. "I look forward to working with our commercial leadership team and expect continued progress of our pre-launchRHEA-AIneutral
10/08/20 4:10 PMNasdaq : KRYSKrystal Biotech to Present Pre-clinical Data Highlighting KB301 for Aesthetic Indications at the ASDS 2020 Virtual MeetingKrystal Biotech, Inc. (Nasdaq:KRYS) today announced the presentation of positive preclinical data supporting the ongoing development of KB301, an innovative, investigational therapy designed to reverse the decline of collagen in aging skin. The data will be presented at the American Society for Dermatologic Surgery (ASDS) 2020 Virtual Meeting to be held October 9-11, 2020. The preclinical program evaluated KB301's ability to transduce clinically relevant skin cells,RHEA-AIneutral
09/09/20 8:00 AMNasdaq : KRYSKrystal Biotech to Present at HC Wainwright and Morgan Stanley Healthcare ConferencesKrystal Biotech Inc. , ("Krystal") (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that Krish S. Krishnan, chairman and chief executiveRHEA-AIneutral
08/17/20 4:01 PMNasdaq : KRYSKrystal Biotech's KB407 Granted Orphan Drug Designation by the FDA to Treat Patients With Cystic FibrosisThe company is on track to file an IND for KB407 in 2021 The company is on track to file an IND for KB407 inRHEA-AIvery positive
07/30/20 8:00 AMNasdaq : KRYSKrystal Biotech to Present at the William Blair BioTech ConferenceKrystal Biotech Inc., ("Krystal") (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that Krish S. Krishnan, chairman and chief executive officer, will be participating in a fireside chat at the William Blair BioTech Conference taking place August 4-6,RHEA-AIneutral
07/28/20 4:44 PMNasdaq : KRYSKrystal Biotech Announces Initiation of Pivotal Phase 3 Study of Beremagene Geperpavec in Patients with Dystrophic Epidermolysis BullosaKrystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced the initiation of GEM-3 study, a multi-center, placebo-controlled, double-blinded, Phase 3 clinical study of beremagene geperpavec ("B-VEC", previously "KB103") for the treatment of dystrophic epidermolysis bullosa (DEB) patients.RHEA-AIvery positive
07/20/20 8:00 AMNasdaq : KRYSKrystal Biotech Appoints Whitney Ijem as Senior Vice President, Strategy and Business DevelopmentKrystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced the appointment of Whitney Ijem to the newly created position of Senior Vice President, Strategy and Business Development. Ms. Ijem joins Krystal from Guggenheim Securities, where she served as Managing Director and Senior Biotechnology Analyst covering genetic medicine and rare disease companies. Ms. Ijem will join Krystal this month and will take a place on the company's leadership team.RHEA-AIneutral
06/08/20 4:01 PMNasdaq : KRYSKrystal Biotech to Present at the Goldman Sachs 41st Annual Global Healthcare Conference WebcastKrystal Biotech Inc., ("Krystal") (NASDAQ: KRYS), a gene therapy company dedicated to developing transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Krish S.RHEA-AIneutral
05/18/20 9:57 PMNasdaq : KRYSKrystal Biotech Announces Pricing of $125 Million Public Offering of Common StockKrystal Biotech, Inc. (Nasdaq: KRYS) (the "Company"), a gene therapy company developing a new class of transformative medicines to treat diseases caused by gene or protein dysfunction, today announced that itRHEA-AIneutral
05/18/20 4:15 PMNasdaq : KRYSKrystal Biotech Announces Proposed Public Offering of Common StockKrystal Biotech, Inc. (Nasdaq: KRYS) (the "Company"), a gene therapy company developing a new class of transformative medicines to treat diseases caused by gene or protein dysfunction, today announced that itRHEA-AIneutral
